white paper
Tapping into APAC's Potential for Obesity Clinical Trials
Jul 23, 2025

Obesity is a growing public health crisis across the Asia Pacific region, yet clinical trial activity remains uneven and underutilized. This whitepaper, Tapping into APAC’s Potential for Obesity Clinical Trials, uncovers the region’s untapped strengths, from diverse patient populations to highly experienced investigators, and explores how pharmaceutical companies can accelerate research in one of the world’s most dynamic therapeutic areas.

Based on IQVIA’s 2025 survey of 138 sites across 10 APAC countries, the findings reveal that over 70% of investigators have more than a decade of experience in obesity-related care, with strong representation from general practitioners, endocrinologists, and internal medicine specialists.

This paper offers actionable insights for biopharmaceutical sponsors and clinical operations teams to optimize site selection, improve recruitment, and navigate regulatory landscapes. Learn how APAC’s treatment-naïve patient pools, multilingual capabilities, and proven site performance can deliver faster, higher-quality trial outcomes.

Download now to unlock new opportunities and help shape the future of obesity research in Asia Pacific.

Related solutions

Contact Us